Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded to Strong-Buy at TD Cowen

TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

DMRA has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Wedbush boosted their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $44.00.

Damora Therapeutics, Inc. Common Stock Trading Down 1.7%

Shares of DMRA stock opened at $30.31 on Monday. The stock has a market cap of $1.87 billion, a P/E ratio of -8.99 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33. The stock has a 50 day simple moving average of $28.50 and a 200 day simple moving average of $26.62.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. Analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.98 EPS for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $40,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Two Sigma Investments LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $76,000. Connective Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $100,000. Finally, Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $266,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.